Pioglitazone Decreases Visceral Fat Metabolism

To Evaluate the Effect of Pioglitazone on Glucose Metabolism of Fat Tissue by Using FDG-PET/CT Imaging Clinical Trial

Official title: Effects of Pioglitazone on Visceral Fat Metabolic Activity

Status Recruiting

Clinical Trial Summary

Excess visceral fat is associated with chronic systemic inflammation and cardiovascular complications. Pioglitazone has been reported to variably influence visceral fat volume, but it its effect on metabolic activity of the visceral fat remains uncharacterized. To evaluate the effect of pioglitazone on glucose metabolism of fat tissue by using 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT) imaging.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• To Evaluate the Effect of Pioglitazone on Glucose Metabolism of Fat Tissue by Using FDG-PET/CT Imaging

• NCT number: NCT01819402
• Study type: Interventional
• Source: Kurume University
• Contact: Nobuhiro Tahara, MD, PhD
• Phone: +81-942-31-7580
• Email: ntahara@med.kurume-u.ac.jp
• Status: Recruiting
• Phase: N/A
• Start date: March 2012